PT-141 10mg

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin-receptor agonist with primary activity at the MC3R and MC4R subtypes, exerting its effects through central nervous system signalling rather than peripheral vascular pathways. This mechanism has placed it at the centre of research into central arousal circuits, sexual health pharmacology and melanocortin-system pharmacology more broadly. The 10mg presentation supports defined laboratory protocols.

Supplied as a lyophilised peptide vial for reconstitution with bacteriostatic water. The 10mg loading is configured for multi-point dose-response work, receptor binding studies and replicated in vitro assay arms within a single, characterised lot.

Research Applications • Central melanocortin pathway and arousal circuit investigation in animal models • MC3R and MC4R receptor binding, selectivity and signalling assays in vitro • Sexual health and reproductive neuropharmacology research applications • Comparative melanocortin agonist pharmacology and structure-activity studies

Specification • Identity: PT-141 / Bremelanotide (CAS 32780-32-8) • Molecular weight: 1025.18 g/mol • Purity: 99%+ verified by HPLC and Mass Spectrometry • Format: lyophilised peptide vial — reconstitute with bacteriostatic water before use • Storage: store lyophilised at -20°C; once reconstituted, refrigerate at 2-8°C and use within 4-6 weeks; protect from light

For research use only — not for human consumption.